
    
      A Randomized Prospective Clinical Trial of Paclitaxel in Combination with Carboplatin Versus
      Paclitaxel plus Epirubicin as First-Line Treatment in Metastatic Breast Cancer. The primary
      endpoints of the study is progression free survival (PFS). The secondary endpoints are
      overall response rate (ORR), overall survival (OS) and safety.
    
  